Latest Breaking News On - Jasonj luke - Page 1 : comparemela.com

Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site

Data Support Adjuvant Pembrolizumab as Standard Care in Stage IIB/C Melanoma

Adjuvant pembrolizumab provides a continued benefit for patients with stage IIB or IIC melanoma at 3 years, updated data suggest.

Data Support Adjuvant Pembrolizumab as Standard Care in Stage IIB/C Melanoma

Adjuvant pembrolizumab provides a continued benefit for patients with stage IIB or IIC melanoma at 3 years, updated data suggest.

KEYNOTE-716: Primary melanoma, not lymph nodes, should 'drive therapeutic decision-making'

CHICAGO — Adjuvant pembrolizumab showed durable benefit vs. placebo among patients with resected stage IIB or IIC melanoma, according to randomized phase 3 study results presented at ASCO Annual Meeting.After more than 3 years of follow-up, patients assigned the anti-PD-1 therapy achieved significantly longer distant metastasis-free survival (DMFS) and RFS, results of the KEYNOTE-716 trial

Expert: KEYNOTE-716 Could be a "Game-Changer" for Patients with Stage 2 Melanoma At High Risk of Recurrence

Until this study, adjuvant immunotherapy was standard of care for stage 3B melanoma but not stage 2, which has relatively similar survival rates and risk of recurrence.